Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

20.30
+0.23001.15%
Post-market: 20.440.1400+0.69%19:53 EDT
Volume:2.81M
Turnover:56.91M
Market Cap:6.48B
PE:42.22
High:20.54
Open:20.19
Low:20.00
Close:20.07
52wk High:21.18
52wk Low:9.56
Shares:319.00M
Float Shares:191.00M
Volume Ratio:0.84
T/O Rate:1.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4808
EPS(LYR):0.2200
ROE:613.02%
ROA:8.60%
PB:196.09
PE(LYR):92.27

Loading ...

UBS Adjusts Amneal Pharmaceuticals Price Target to $23 From $19, Maintains Buy Rating

MT Newswires Live
·
Jul 15

Amneal Pharmaceuticals price target raised to $23 from $19 at UBS

TIPRANKS
·
Jul 15

Amneal Pharmaceuticals to Report Second-quarter 2026 Results, Host Webcast

Reuters
·
Jul 10

Amneal, Adalvo Win FDA Review Acceptance for Generic Tirzepatide Autoinjector Andas

Reuters
·
Jul 09

Did EMA’s Positive Hopledo Ruling Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative?

Simply Wall St.
·
Jul 08

Amneal Pharmaceuticals (AMRX) Gets EU Backing For Hopledo, Is It Fully Priced?

Simply Wall St.
·
Jul 03

Rocket Pharma Names Joseph Manhede Principal Accounting Officer, Effective July 8

Reuters
·
Jul 01

US FDA - Amneal, Cellares, Eli Lilly, Fujifilm, Kriya, Kyowa Kirin, Regeneron Join FDA Precheck Pilot

THOMSON REUTERS
·
Jun 30

Lilly, Regeneron Selected for US Program to Review New Manufacturing Plants Faster

Reuters
·
Jun 30

Eli Lilly, Regeneron among first selections for FDA PreCheck program, CNBC says

TIPRANKS
·
Jun 30

Amneal Pharmaceuticals, Zambob's Parkinson's Treatment Recommended by European Committee for Approval

MT Newswires Live
·
Jun 29

Zambon and Amneal Announce Positive Chmp Opinion for Hopledo® (ipx203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations

THOMSON REUTERS
·
Jun 29

Amneal Partner Zambon Wins Positive EU CHMP Opinion for Parkinson’s Drug Hopledo

Reuters
·
Jun 29

FDA Seeks Updated Labeling for Testosterone Therapies

MT Newswires Live
·
Jun 19

Amneal (AMRX) Stock Valuation Check After Strong Multi Period Gains And Conflicting Fair Value Models

Simply Wall St.
·
Jun 14

A Look At Amneal Pharmaceuticals (AMRX) Valuation After Romidepsin Approval And Positive CREXONT Trial Data

Simply Wall St.
·
Jun 06

BUZZ-U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia

Reuters
·
Jun 05

Amneal Pharmaceuticals' Reports Crexont Provides Clinical Benefit Over Rytary in Phase 4 Interim Results

MT Newswires Live
·
Jun 05

BUZZ-Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study

Reuters
·
Jun 05

Amneal says interim Phase 4 ELEVATE-PD data show Crexont adds about 3 hours daily “Good On” time in Parkinson’s patients

Reuters
·
Jun 05